Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2011;33(1):31-4.
doi: 10.5581/1516-8484.20110011.

Cost of the treatment of myelodisplastic syndrome in Brazil

Otávio Clark  1 , Enéas José de Matos Faleiros
Affiliations

Cost of the treatment of myelodisplastic syndrome in Brazil

Otávio Clark et al. Rev Bras Hematol Hemoter. 2011.

Abstract

Introduction: Myelodysplastic syndrome is an incurable and rare hematological disease that affects the production of blood cells. One aim of treatment is to maintain the blood-cell count to near-normal levels. This is mainly achieved with hematopoietic- growth factors and transfusions. Our objective was to determine the cost of supportive treatment/care for patients with low and intermediate I risk myelodysplastic syndrome in respect to private healthcare plans in Brazil.

Method: We adapted the National Comprehensive Cancer Network treatment guidelines for intermediate risk myelodysplastic syndrome patients to the Brazilian reality, adopting a decision tree to explore treatment combinations. Then, we calculated the costs for each branch of the tree, according to national prices. We also estimated total costs for a cohort of 100 patients, distributed across treatment combinations according to the expected epidemiology. We assumed a horizon of one year of treatment.

Results: The mean cost of treatment for low and intermediate I risk myelodysplastic syndrome is US$ 42,758/patient/year. This cost can vary from US$ 24,282 to US$ 121,952, according to patient characteristics and the treatment used. Overall, patients that require immunotherapy with antithymocyte globulins are associated with the highest cost. Those that achieve disease stability solely with the use of erythropoietin were associated with the lowest cost.

Conclusion: In Brazil, treatment of low and intermediate I risk myelodysplastic syndrome is associated with a mean cost of the order of US$ 42,700/patient/year. New types of therapy have the potential to change this scenario if they can diminish the requirements for supportive care.

Keywords: Cost of illness; Hematologic neoplasms; Neoplasms.

PubMed Disclaimer

Conflict of interest statement

Conflicts of interest: Both authors, Otávio Clark and Enéas Faleiros, work for Evidências Consultoria , Campinas(SP), Brazil

Figures

Figure 1
Figure 1
Treatment of MDS, with the probabilities, percentage of response, treatment used and total cost for all patients for each pathway over one year according to this model. MDS: Myelodisplastic syndrome; Chemo: chemotherapy; EPO: erythropoietin; CSF: colony stimulating factors; IT: immunotherapy. The number between square brackets [ ] means the number of the pathway and the number in brackets ( ) means the number of patients in each treatment arm
See this image and copyright information in PMC

References

    1. Sekeres MA.The epidemiology of myelodysplastic syndromes Hematol Oncol Clin North Am 201024 (2): 287-294 - PubMed
    1. Steensma DP.Novel therapies for myelodysplastic syndromes Hematol Oncol Clin North Am 201024 (2): 423-441 - PubMed
    1. Greenberg PL, Cosler LE, Ferro SA, Lyman GH.The costs of drugs used to treat myelodysplastic syndromes following National Comprehensive Cancer Network Guidelines J Natl Compr Canc Netw 20086 (9): 942-953 - PubMed
    1. Cazzola M, Malcovati L.Prognostic classification and risk assessment in myelodysplastic syndromes Hematol Oncol Clin North Am 201024 (2): 459-468 - PubMed
    1. Greenberg P.Clinical Practice Guidelines in Oncology: Myelodysplatic Syndromes National Comprehensive Cancer Network; 2009. Available at: http://www.nccn.org

LinkOut - more resources